Mergermarket | Interview with Dr James Campbell


Patrys CEO and MD, Dr James Campbell, was recently interviewed by Louise Weihart at Mergermarket, to discuss the deal potential of its deoxymab platform as it heads towards its first clinical trial in mid 2023.

Here’s an excerpt from the article:

“Patrys was already having early licensing, co-development and M&A conversations with global pharmas and biotechs but is now seeing more interest in the highly transacted biologics antibody space, which sees some 60% of deals executed at preclinical stage compared with only 35% of small molecule deals taking place before first-in-human studies, Campbell said.”

Click here to read the full article.